Αποτελέσματα Αναζήτησης
Current treatment considerations include use as single-agent therapy (with prednisone), in combination with multiagent chemotherapy protocols, and/or as maintenance therapy after completion of multiagent chemotherapy protocols in dogs with naïve or previously treated lymphoma.
12 Σεπ 2023 · A case-controlled design comparing 2-year remission and survival rates between dogs treated with CHOP-based chemotherapy and those treated with chemotherapy and sequential low-dose rate half-body irradiation.
Survival periods are highly variable. Prolonged MSTs and high 1 and 2 yr survival rates have been reported in ‘‘high risk’’ patients receiving vinblastine. TKIs produce a high response rate in grossly measurable tumors; survival data in patients at high risk for metastases have not been reported.
This treatment is a new approach that uses short pulses of electrons at ultra-high-dose rates to deliver a large dose of radiation in just a fraction of a second. “The idea is to protect normal tissue and simultaneously maximize the anticancer effects,” Dr. Clendenin explains.
A recent study examined the use of GCs alone in the treatment of naïve peripheral nodal B-cell and T-cell canine lymphoma and found that the overall survival time was 50 days (95% confidence interval [CI], 41 to 59 days).
Introduction. Cancer immunotherapy continues to make remarkable strides in just the few years since the first checkpoint molecule targeted therapeutic antibodies were evaluated in trials and approved by the FDA.
There are 3 common treatment options for animal cancer and tumor: surgery, chemotherapy, and radiation therapy (also called radiotherapy). Each of these options can be used alone or in combination with other treatments. The specific treatment program your veterinarian will recommend will depend on the specifics of your pet’s condition.
